For licensed medical professionals and compounding pharmacies only. Not for sale to the general public.  ·  787-822-8197
Build Your Order Apply for Wholesale
Build Your Order Products For Clinics For Pharmacies For Brands Quality Wholesale Resources About Contact Apply for Wholesale
Product sourcing reference

Retatrutide / Cagrilintide Blend

A combination reference pairing two investigational compounds. Neither component is an approved medicine, so the request needs an explicit eligibility review.

Reference variants

Add Retatrutide / Cagrilintide Blend to an order request

Quantities are individual vials (packs of 10). Orders need 100 vials and/or 20 spray bottles in total, mixed across items. Prices are reference estimates captured 2026-10-16; every request is pending eligibility and availability review. Per-unit figures are rounded to the cent from kit pricing, so a final quote may differ slightly.

  • 10mg (5/5)Vial · confirm physical formCAS Multi-component
    $14.95/vialCloseout estimate Regular $29.90. Subject to confirmation; not a stock promise.
    vials, packs of 10

Review your order request · Compare the full catalog

Confirm the exact substance

Retatrutide is a multi-receptor agonist in clinical development and cagrilintide is an amylin analogue in development. The combined format is a supplier formulation, not a studied clinical product.

What the review will ask

Expect the review to focus on intended use, the requesting facility type and whether any permitted pathway exists for either investigational component.

  • State the facility type, destination state and intended transaction. Do not send patient information.
  • Expect product- and lot-specific documentation to be requested before any material is accepted.
  • A listed price is a reference estimate. Availability, labeling, shipping and terms are confirmed in writing only after review.

Purchasing questions

Has this combination been studied as one product?

We are not aware of an approved or established clinical product with this exact pairing. Treat it as an investigational combination requiring case-by-case review.

Two restricted components do not create a new pathway

FDA identifies both retatrutide and cagrilintide as substances that cannot be used in compounding under federal law. Combining their names or quantities does not change that restriction.

Documentation to request

Require separate identity records for both components; do not interpret the combined reference price as clinical availability.

Regulatory context: FDA: unapproved GLP-1 drugs and ingredient restrictions. Source reviewed . This source does not verify the identity, testing or availability of our catalog references.

Related guidance: Weight-loss clinic sourcing requirements. These references support a review, not a treatment recommendation or supply authorization.

Verify the current regulatory position

Use FDA human drug compounding guidance and applicable state requirements. This reference is not medical or legal advice and does not establish a lawful supply route.

Discuss sourcing requirements
Call Apply for Wholesale